Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Naoyuki Akashi, Tomio Umemoto, Hodaka Yamada, Takayuki Fujiwara, Kei Yamamoto, Yousuke Taniguchi, Kenichi Sakakura, Hiroshi Wada, Shin-ichi Momomura & Hideo Fujita. (2023) Teneligliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells. Diabetes, Metabolic Syndrome and Obesity 16, pages 1043-1054.
Read now
Read now
Harmanjit Singh, Jasbir Singh, Ravneet Kaur Bhangu, Mandeep Singla, Jagjit Singh & Farideh Javid. (2023) Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects. Expert Review of Clinical Pharmacology 16:1, pages 49-59.
Read now
Read now
Yosuke Takamiya, Keisuke Okamura, Kazuyuki Shirai, Tetsu Okuda, Kunihisa Kobayashi & Hidenori Urata. (2020) Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T). Clinical and Experimental Hypertension 42:3, pages 197-204.
Read now
Read now
S Erande, S Sarwardekar & B Desai. (2019)
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study). Diabetes, Metabolic Syndrome and Obesity 12, pages 961-967.
Read now
Read now
Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Makoto Ueno, Miyuki Matsukawa, Tomoko Yamakura, Kazuyo Sasaki, Mayumi Kimura & Hiroaki Iijima. (2018) Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 19:2, pages 83-91.
Read now
Read now
Takashi Kadowaki, Kazuoki Kondo, Noriyuki Sasaki, Kyoko Miyayama, Shoko Yokota, Ryuji Terata & Maki Gouda. (2017) Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opinion on Pharmacotherapy 18:13, pages 1291-1300.
Read now
Read now
André J. Scheen. (2016) DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1407-1417.
Read now
Read now
Andrew Bryson, Paul E Jennings, Laszlo Deak, Fraga S Paveliu & Matt Lawson. (2016) The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension. Expert Opinion on Pharmacotherapy 17:10, pages 1309-1316.
Read now
Read now
Articles from other publishers (23)
Takashi Kadowaki, Nobuya Inagaki, Hirotaka Watada, Kazuyo Sasaki, Kazumi Mori-Anai, Tomohisa Iwasaki & Tatsuki Teranishi. (2022) Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan. Advances in Therapy 39:4, pages 1642-1658.
Crossref
Crossref
Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyung Wan Min, Eun Jung Kyung, Yeo Kyeong Kim & Kwan Woo Lee. (2021) Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study. Diabetes Therapy 12:11, pages 2907-2920.
Crossref
Crossref
Cheol Son, Hisashi Makino, Masato Kasahara, Tomohiro Tanaka, Kunihiro Nishimura, S. Taneda, Takeshi Nishimura, Shu Kasama, Yoshihiro Ogawa, Yoshihiro Miyamoto & Kiminori Hosoda. (2021) Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium–glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study. Diabetes Research and Clinical Practice 180, pages 109037.
Crossref
Crossref
Tomoya Ueda, Shu Kasama, Masahiro Yamamoto, Tomoya Nakano, Kazuhiro Ueshima, Yoshinobu Morikawa, Hiroyuki Kawata, Akiomi Yoshihisa, Masafumi Nakayama, Sei Komatsu, Tsunenari Soeda, Makoto Watanabe, Rika Kawakami, Yasushi Okada, Hiroyuki Tanaka, Yutaka Susuta, Masato Kasahara, Kenichi Tsujita, Yasuchika Takeishi & Yoshihiko Saito. (2021) Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes. Circulation Reports 3:8, pages 440-448.
Crossref
Crossref
Shrikrishna V. Acharya. (2020) Is Teneligliptin Safe in Patients with Diabetes Mellitus Mainly with Reference to QT Prolongation. Journal of Evolution of Medical and Dental Sciences 9:31, pages 2171-2175.
Crossref
Crossref
Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Kazuyo Sasaki & Yuka Yamada. (2020) Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan. Advances in Therapy 37:5, pages 2477-2492.
Crossref
Crossref
Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Kazuyo Sasaki, Miyuki Matsukawa & Yuka Yamada. (2019) Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan. Advances in Therapy 37:3, pages 1065-1086.
Crossref
Crossref
Shu Kasama, Tohru Masuyama, Shiro Uemura, Yukihito Sato, Shinya Hiramitsu, Izuru Masuda, Kazuhiro Yamamoto, Sei Komatsu, Toshihisa Anzai, Kunihiro Nishimura, Tomoya Ueda, Masato Kasahara, Hiroyuki Tanaka, Yutaka Susuta & Yoshihiko Saito. (2019) Rationale and Design of the CANONICAL Study ― Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus ―. Circulation Reports 1:8, pages 347-351.
Crossref
Crossref
Antonio Ceriello, Valeria De Nigris, Hiroaki Iijima, Takahiro Matsui & Maki Gouda. (2019) The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. Drugs 79:7, pages 733-750.
Crossref
Crossref
Masakazu Haneda, Takashi Kadowaki, Hiroshi Ito, Kazuyo Sasaki, Sonoe Hiraide, Manabu Ishii, Miyuki Matsukawa & Makoto Ueno. (2018) Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance. Diabetes Therapy 9:3, pages 1083-1097.
Crossref
Crossref
Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Kazuyo Sasaki, Sonoe Hiraide, Miyuki Matsukawa & Makoto Ueno. (2018) Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients. Advances in Therapy 35:6, pages 817-831.
Crossref
Crossref
Takashi Kadowaki, Kazuyo Sasaki, Manabu Ishii, Miyuki Matsukawa & Yoshiteru Ushirogawa. (2018) Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies. Diabetes Therapy 9:2, pages 623-636.
Crossref
Crossref
Valeria De Nigris, Francesco Prattichizzo, Elettra Mancuso, Rosangela Spiga, Gemma Pujadas & Antonio Ceriello. (2017) Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions. Oncotarget 9:10, pages 8898-8910.
Crossref
Crossref
Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Maki Gouda, Hiroaki Iijima & Yumi Watanabe. (2017) Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study. Diabetes, Obesity and Metabolism 20:2, pages 453-457.
Crossref
Crossref
Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Yumi Watanabe, Maki Gouda & Hiroaki Iijima. (2017)
Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in
J
apanese patients with type 2 diabetes
. Diabetes, Obesity and Metabolism 20:1, pages 77-84.
Crossref
Crossref
André J. Scheen. (2016) Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clinical Pharmacokinetics 56:7, pages 703-718.
Crossref
Crossref
Gemma Pujadas, Valeria De Nigris, Francesco Prattichizzo, Lucia La Sala, Roberto Testa & Antonio Ceriello. (2016) The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. Endocrine 56:3, pages 509-520.
Crossref
Crossref
T. Biftu & R. SinhaRoy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
512
555
.
Lesley J. Scott. (2016) Teneligliptin in type 2 diabetes: a guide to its use in Argentina. Drugs & Therapy Perspectives 32:3, pages 85-90.
Crossref
Crossref
Manish Maladkar, Srividya Sankar & Kushal Kamat. (2016) Teneligliptin: Heralding Change in Type 2 Diabetes. Journal of Diabetes Mellitus 06:02, pages 113-131.
Crossref
Crossref
Enrique Z. Fisman & Alexander Tenenbaum. (2015) Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Lesley J. Scott. (2015) Teneligliptin: A Review in Type 2 Diabetes. Clinical Drug Investigation 35:11, pages 765-772.
Crossref
Crossref
Mikhail Blagosklonny & Andrei Gudkov. (2010) Introducing, OncoTarget. Oncotarget 1:1, pages 2-2.
Crossref
Crossref